| scholarly article | Q13442814 |
| P2093 | author name string | Bin Yu | |
| Phillip W Berman | |||
| Javier F Morales | |||
| Kathryn A Mesa | |||
| David L Alexander | |||
| Gerardo Perez | |||
| P2860 | cites work | B Cell Epitope Mapping of Human Immunodeficiency Virus Envelope Glycoproteins with Long (19- to 36-residue) Synthetic Peptides | Q43950591 |
| Effect of proline and glycine residues on dynamics and barriers of loop formation in polypeptide chains | Q45310103 | ||
| Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group | Q45752018 | ||
| Interplay between hydrophobic cluster and loop propensity in beta-hairpin formation | Q73441806 | ||
| Beta-and gamma-turns in proteins revisited: a new set of amino acid turn-type dependent positional preferences and potentials | Q73950065 | ||
| Minimal model systems for beta sheet secondary structure in proteins | Q77891983 | ||
| A revised set of potentials for beta-turn formation in proteins | Q24675540 | ||
| Recent strategies targeting HIV glycans in vaccine design | Q26823603 | ||
| Structural insights on the role of antibodies in HIV-1 vaccine and therapy | Q26829461 | ||
| A Blueprint for HIV Vaccine Discovery | Q26829865 | ||
| Antibodies in HIV-1 vaccine development and therapy | Q27011574 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 | Q27662167 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope | Q27664365 | ||
| Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies | Q27674878 | ||
| Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Q27675879 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Proof of principle for epitope-focused vaccine design | Q27681593 | ||
| Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells | Q28288205 | ||
| Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies | Q28602877 | ||
| Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding | Q28728517 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line | Q29616392 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Loop sequence dictates the secondary structure of a human membrane protein hairpin | Q30155125 | ||
| Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells | Q30419448 | ||
| Stabilization of beta-hairpin peptides by salt bridges: role of preorganization in the energetic contribution of weak interactions | Q30959309 | ||
| Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites | Q33614461 | ||
| Transplanting supersites of HIV-1 vulnerability | Q33854841 | ||
| HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 | Q33947008 | ||
| Production of recombinant protein therapeutics in cultivated mammalian cells | Q33982884 | ||
| beta-hairpin-forming peptides; models of early stages of protein folding | Q34005468 | ||
| Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation | Q34141693 | ||
| Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 | Q34298408 | ||
| The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. | Q34303849 | ||
| Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. | Q34335632 | ||
| Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial | Q34374835 | ||
| Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials | Q34396095 | ||
| Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection | Q34402934 | ||
| Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial | Q34562259 | ||
| Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positio | Q34583767 | ||
| Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop | Q34742533 | ||
| Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes | Q35034268 | ||
| HIV vaccines 1983-2003. | Q35166836 | ||
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors | Q35382871 | ||
| HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen | Q35969973 | ||
| Increasing protein conformational stability by optimizing beta-turn sequence | Q36156342 | ||
| A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies | Q36171938 | ||
| HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. | Q36345558 | ||
| Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1 | Q36653818 | ||
| Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. | Q36692987 | ||
| Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1 | Q36699076 | ||
| Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. | Q37063013 | ||
| Roles of beta-turns in protein folding: from peptide models to protein engineering | Q37084770 | ||
| Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. | Q37318213 | ||
| Optimal and consistent protein glycosylation in mammalian cell culture | Q37506963 | ||
| Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. | Q37644030 | ||
| Challenges for structure-based HIV vaccine design | Q37667763 | ||
| Antibody B cell responses in HIV-1 infection | Q38252874 | ||
| Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens | Q38581943 | ||
| Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. | Q38631979 | ||
| Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. | Q38905596 | ||
| Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120 | Q39357299 | ||
| Glycosylation site-specific analysis of clade C HIV-1 envelope proteins | Q39824069 | ||
| Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand | Q41709217 | ||
| Increasing protein stability by improving beta-turns | Q42095915 | ||
| Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. | Q42215329 | ||
| Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. | Q43096886 | ||
| P304 | page(s) | 14-25 | |
| P577 | publication date | 2016-07-21 | |
| P1433 | published in | Molecular Immunology | Q6895954 |
| P1476 | title | Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody | |
| P478 | volume | 77 |
| Q46148243 | Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. |
| Q57817932 | Development of a Stable MGAT1 CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies |
| Q90466213 | Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity |
| Q37448281 | Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits |
| Q55518743 | Towards conformational fidelity of a quaternary HIV-1 epitope: computational design and directed evolution of a minimal V1V2 antigen. |
| Q92479131 | Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies |
| Q40130441 | Using homology modeling to interrogate binding affinity in neutralization of ricin toxin by a family of single domain antibodies |
Search more.